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Abstract
Colorectal cancer (CRC) is one of the commonest can-
cers with 1.2 million new cases diagnosed each year in 
the world. It remains the fourth most common cause 
of cancer-related mortality in the world and accounts 
for > 600000 cancer-related deaths each year. There 
have been significant advances in treatment of meta-
static CRC in last decade or so, due to availability of 
new active targeted agents and more aggressive ap-
proach towards the management of CRC, particularly 
with liver-only-metastases; however, these drugs work 
best when combined with conventional chemotherapy 
agents. Despite these advances, there is a lack of bio-
markers to inform us about the accurate management 
of the patients with metastatic CRC. It is therefore 
imperative to carefully select the patients with com-
prehensive multi-disciplinary team input in order to 
optimise the management of these patients. In this 
review we will discuss various treatment options avail-
able in management of colorectal liver metastases with 
potential guidance on how and when to choose these 
options along with consideration on future directions in 
management of this disease.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Colorectal cancer is one of the commonest 
cancers in the world. The management of metastatic 
colorectal cancer has changed significantly in last 
decade or so; primarily based on better understand-
ing of the molecular complexity of colorectal cancer 
coupled with aggressive approach in management of 
colorectal liver metastases. Colorectal liver metasta-
sises were once considered as incurable disease but 
with better treatment options and valuable input from 
multi-disciplinary teams, this disease can be cured in a 
proportion of patients. This review takes into account 
various clinical scenarios and their complexity that the 
clinicians may face during management of this disease.
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INTRODUCTION
Colorectal cancer (CRC) is a leading cause of  cancer-
related mortality in the world with over 1.2 million new 
cases diagnosed each year along with > 600000 death 
per year[1,2]. Curative surgery is the mainstay of  treat-
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ment for early stage CRC with pathological staging be-
ing considered as the most important predictor of  post-
operative outcome. Majority of  the patients could have 
relatively good outcomes with 5-year survival ranging 
from 50%-90%[3] depending upon the initial stage of  the 
disease and other prognostic factors; however, despite 
significant improvements in screening and management 
of  CRC in recent times, the 5-year survival rate for pa-
tients with metastatic CRC (mCRC) remains poor[4]. In 
these patients, the prognosis is closely related to the lo-
cation and extent of  distant metastatic disease.
In patients with unresectable mCRC, improvement 
in survival from 12 mo with fluorouracil therapy to ap-
proximately 2 years has been observed with combinations 
with oxaliplatin (FOLFOX) or it’s pro-drug capecitabine 
(CAPOX), or with irinotecan (FOLFIRI)[5-8]. Recent 
randomised control trials suggested that median overall 
survival (OS) of  over 30 mo can now be achieved[9,10] in 
patients with mCRC. Approximately 50% of  the patients 
tend to have involvement of  liver during the course of  
their disease[11,12] and a proportion of  them with colorec-
tal liver-only metastases (CLM) can undergo liver metas-
tasectomy; this could result in significant improvement 
in their outcomes. Many patients however develop liver 
metastases which are unresectable. Earlier reports sug-
gested that with oxaliplatin-based chemotherapy, 13% 
of  patients with initially non-resectable liver metastases 
could have their disease resected after chemotherapy[13]. 
Five- and ten-year overall survival rates of  33% and 
27% have been observed respectively in this cohort of  
patients[14]. Moreover, approximately 15% of  patients 
never developed recurrent disease, thus they were con-
sidered “cured”[15]. Furthermore, liver resection rate after 
chemotherapy correlates significantly with radiological 
objective response rate (ORR)[16] and in addition resected 
patients enjoy significantly prolonged survival compared 
to those who can’t undergo resection[17].
The treatment options for CLM include (Figure 1): 
surgical resection, systemic chemotherapy, localised treat-
ment options: radiofrequency ablation (RFA), selective 
internal radiotherapy (SIRT), chemoembolization, other 
local ablative methods.
In this review we will discuss the most common 
treatment options with particular emphasis upon the 
role of  systemic therapy in CLM, either deemed resect-
able or un-resectable at the initial presentation. We will 
also discuss the key molecular pathways and emerging 
areas of  interest that may provide new opportunities for 
therapeutic intervention in this context.
CURRENT TREATMENT OPTIONS
Surgical resection of CLM
If  CLM are amenable to surgery, then this can be offered 
with curative intent. Post metastasectomy the 5-year sur-
vival rates vary between 27%-58% and 10-year survival 
rates are 15%-17%[18-29]; Post-operative complication rates 
are higher in patients undergoing simultaneous hepatic 
and colonic resections of  the synchronous tumours. 
However, in most high volume surgical centres with ex-
perience in CLM metastasectomy, surgical mortality rates 
are reported to be less than 5%[30,31]. The modern ap-
proach to resectability of  CLM has largely changed with 
emphasis of  most MDT decisions in favour of  offering 
surgery to the patients, in the absence of  extra-hepatic 
disease. Due to its clear impact on overall outcome, surgi-
cal resection is the treatment of  choice, where possible; 
however, these decisions should be made after compre-
hensive discussion in the regional hepato-biliary MDT.
Resectability criteria and prognostic factor: Although 
there is published literature on various treatment ap-
proaches, universal agreement on the resectability criteria 
in the context of  CLM, remains not well defined. The 
distinction between resectable and non-resectable CLM 
varies from institute to institute and this was highlighted 
in the large CELIM study which identified 64.5% dis-
cordance within a board of  surgeons when they were 
blinded to baseline or post-treatment scans and patient 
clinical outcomes; this included 6.8% disagreement in 
critical decisions of  resectability vs non-resectability[32]. 
Some authors have defined risk-scoring systems to guide 
the MDTs about the patient selection, but most MDTs 
rely on clinical assessment and local surgical expertise 
rather than the set scoring criteria. This reflects on the 
heterogeneity of  patient population treated within the 
context of  different clinical trials and lack of  reliable 
data to inform us about the prognostic factors being ex-
amined in these trials.
One of  the commonly used scoring system to help 
patient selection was described by Fong and colleagues[33], 
where a retrospective review of  1001 patients after hepatic 
resection for mCRC was conducted. In this study clinical, 
pathological and outcome data were collected. Five year 
and 10-year survival rates were 37% and 22% respectively. 
The authors identified seven independent factors includ-
ing positive margins, extra-hepatic disease, node-positive 
primary, disease-free survival from primary to metastatic 
disease, number of  hepatic tumour > 1, largest tumour > 
5 cm and carcinoembryonic antigen > 200 ng/mL which 
were found to be predictive of  survival. The last five of  
the above factors were combined to form a prognostic 
score, with each factor assigned one point. The combined 
score was found to be highly predictive of  the outcome. 
Patients with < 2 score had a favourable outcome; those 
with three, four or five criteria were recommended to 
be considered for adjuvant chemotherapy trials in view 
of  high risk and poor outcomes. Patients with score of  
5 had 5-year survival of  14% with a median survival of  
22 mo compared to 44% and 51 mo in patients with one 
risk factor. This score however only was validated for pa-
tients with upfront resection and doesn’t include patients 
who underwent preoperative chemotherapy; its validity 
in modern treatment paradigm is therefore often limited. 
Following that many scoring systems have been devel-
oped but none of  them have been validated and thus have 
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limited utility in clinical practice[34,35].
The limitations for hepatic resection in general are 
considered to be, based on one of  the following: (1) no 
upfront R0 resection of  all hepatic lesions possible; (2) 
less than 30% estimated residual liver after resection; 
(3) disease in contact with major vessels of  the remnant 
liver (vessels remaining after potential hepatectomy); (4) 
significant co-morbidities excluding surgery; and/or (5) 
presence of  extra-hepatic disease.
Detection of  number and location of  metastases: 
Based on several retrospective analyses, in the past, num-
ber of  metastatic sites was considered as one of  the major 
contraindications to hepatic resection in CLM but with 
modern surgical techniques and more encouraging role 
of  preoperative chemotherapy, patients could still be 
deemed resectable with multiple CLM; although several 
studies have identified the prognostic value of  number of  
metastatic sites at initial presentation[36,37]. Furthermore, 
bilobar involvement previously deterred the surgeons 
from offering curative hepatic resection but these con-
cepts have been challenged by several other groups[28,38-42]. 
Additionally, one of  the classic contraindication to surgery 
in CLM is considered to be portal node metastases due to 
an old perception that these patients were at higher risk 
of  developing systemic disease; however, this concept has 
again been challenged in recent times, with several authors 
recognising that although this could be considered a poor 
predictor of  outcome but can not be considered an ab-
solute contraindication to hepatectomy[43,44]. Similarly, the 
presence of  limited extra-hepatic metastatic disease is no 
longer considered an absolute contraindication to surgery; 
however, the outcomes may not be as favourable as with 
CLM or thoracic metastases alone[45-47].
Importance of  imaging modalities: The above discus-
sion highlights the importance of  having detailed base-
line information about the actual extent of  the disease 
in order to make best possible decisions for the patients. 
Modern techniques of  imaging including contrast-en-
hanced computed tomography (CT), contrast enhanced 
magnetic resonance imaging (MRI) scan of  the liver and 
whole body positron emission tomography (PET) with 
computed tomography (PET-CT) have made significant 
contributions in assessment of  resectability of  CLM. How-
ever, PET-CT is limited in the diagnosis of  liver metasta-
ses smaller than 1cm[48]. A large meta-analysis[49] including 
39 studies with 3391 patients examined the sensitivity 
estimates of  CT, MRI and fludeoxyglucose FDG PET on 
per-lesion basis. All included patients had histologically 
proven CRC along with CLM. The study showed 74.4%, 
80.3% and 81.4% sensitivity respectively; however on per-
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Colorectal liver only metastases
Suitable for R0 resection Borderline or unsuitable for upfront R0 resection
Surgery Suitable for surgery Not suitable for surgery
Offer 12 wk of neo-adjuvant 
chemotherapy (doublet or triplet) with 
anti-VEGF or anti-EGFR therapy
Discussion in MDT re: suitability of resection, 
utilising imaging modalities including CT 
scan, MRI scan and whole body PET scan
SD/PR, consider 12 wk 
of further chemotherapy 
± localised treatment 
options”
PD or intolerability: 
stop treatment and 
consider alternative 
chemotherapy
Following R0 resection, 
consider adjuvant 
chemotherapy
Consider 12 wk of neo-adjuvant 
chemotherapy (mostly doublet ± anti-
VEGF therapy)
Follow up until deathfollow up for ten years
Figure 1  The treatment options for colorectal liver-only metastases. MDT: Multi-disciplinary team; CT: Computed tomography; PET: Positron emission tomog-
raphy; MRI: Magnetic resonance imaging; VEGF: Vascular endothelial growth factor; EGFR: Epidermal growth factor receptor; PD: Progressive disease; SD: Stable 
disease; PR: Partial response.
Khan K et al . Colorectal cancer with liver metastases
patient basis the sensitivity was 83.6%, 88.2% and 94.1% 
with three modalities respectively. Per-patient sensitivity 
of  CT was found to be lower than FDG PET (P = 0.025). 
For lesions smaller than 10 mm, the sensitivity estimates 
for MR imaging were better than CT scan; no difference 
was seen for lesion above 10 mm. The study authors con-
cluded that the MRI scan was better imaging modality for 
detection of  liver metastases; however, limited data were 
available on FDG PET.
Given the sensitivity of  MRI scan of  the liver is prov-
en to be superior to CT scan, even in the presence of  
new generation CT scanners using triple phase imaging 
with contrast administration, multiple imaging modali-
ties including both CT and MRI scans are often used in 
evaluation of  CLM. Additionally, the apparent diffusion 
coefficient (ADC), derived from diffusion-weighted 
MRI (DW-MRI), may provide information on predicting 
response to chemotherapy[50,51]. Our group performed a 
recent retrospective series including 102 patients, who 
underwent pre-treatment DW-MRI; we found that the 
CLM with higher pre-treatment mean ADC were as-
sociated with poorer response to chemotherapy but this 
didn’t co-relate with the outcome of  the patients. This 
technique can nevertheless be utilised in clinical setting 
especially in patients undergoing neo-adjuvant chemo-
therapy[52].
FDG-PET scan is considered to be more sensitive 
investigation than CT for detection of  metastatic disease 
and thus can have an impact in the clinical management 
of  CLM patients. A pooled analysis on six previously re-
ported articles showed that the sensitivity and specificity 
of  FDG PET for hepatic disease were 79.9% and 92.3% 
compared to 82.7% and 84.1% with CT scan; for extra-
hepatic disease those were 91.2% and 98.4% with PET 
scan compared to 60.9% and 91.1% with CT respectively. 
This had a significant impact on clinical management 
in 25% of  the cases[53]. Subsequent studies showed that 
the use of  PET as an adjunct to CT could be associated 
with alteration in patient’s management in one-third of  
the patients[54].
These data indicate that treatment approach in CLM 
could be significantly influenced by the extent and re-
sectability of  disease; therefore, multiple imaging mo-
dalities should be considered, in order to optimise the 
management of  patients with CLM and indeed in order 
to avoid un-necessary surgical morbidity and mortality.
Systemic therapy options for CLM
Neo-adjuvant chemotherapy for clearly R0 resect-
able CLM: Surgical resection is regarded as the standard 
of  care for patients with CLM, but relapse is common. 
Patients with potentially resectable CLM can therefore 
be considered for neoadjuvant chemotherapy. Recent 
data, however suggests that the initial advantage seen 
in progression free survival (PFS) for patients receiving 
additional systemic treatment may not actually translate 
into a meaningful OS advantage[55]. EORTC 40983[56] is 
the largest randomised double blinded trial examining 
the role of  neo-adjuvant chemotherapy in this context. 
This trial recruited 364 patients with 1:1 randomisa-
tion to FOLFOX4 [fluorouracil (5-FU)/leucovorin and 
oxaliplatin] six cycles before and six cycles after surgery 
(n = 182) vs upfront surgery alone (n = 182). Patients 
assigned to chemotherapy arm had an ORR of  36% 
with four patients achieving a complete response (CR). 
Eleven patients progressed, of  which 8 were no longer 
resectable. Eighty-three percent patients were resected 
after a median of  6 cycles of  preoperative chemotherapy 
compared to 84% in the surgery group. The absolute in-
crease in progression free survival at 3 years for patients 
undergoing liver resection after chemotherapy was 9.2%. 
Reversible complications occurred more frequently in the 
chemotherapy group (25% vs 16%); however, no impact 
on post-operative mortality was observed. Five year OS 
improvement of  4.1% with median OS of  64 mo (vs 55 
mo) in favour of  chemotherapy arm was observed; how-
ever, this was not statistically significant. It is however 
worth-noting that the trial was not powered to detect OS 
benefit. Furthermore a recent retrospective study analys-
ing 466 patients with CLM, concluded that there was no 
significant difference observed between the outcomes 
of  the patients receiving preoperative neoadjuvant che-
motherapy compared with those who didn’t receive neo-
adjuvant treatment[57]. This study had however serious 
limitations including the retrospective nature of  the study, 
imbalanced sample size between the two groups and het-
erogeneity of  the patient population treated in the study.
Although these data show that the benefit for upfront 
chemotherapy in patients with CLM remains controver-
sial; decision about scope of  systemic therapy must be 
made on case-to-case basis with consideration of  tumour 
biology, previous response and PFS on chemotherapy in 
the event of  metachronous CLM, other co-morbid con-
ditions and local surgical expertise.
Conversion chemotherapy for borderline CLM: Most 
patients with CLM may present with extensive hepatic 
disease which may not be amenable to surgery. These 
patients require systemic chemotherapy, either given with 
palliative intent or as neo-adjuvant treatment to down-
size their tumours in order to make them operable. This 
treatment is referred to as, “conversion therapy (Figure 
2)”. Three conventional cytotoxic drugs are available for 
treatment of  mCRC: fluoropyrimidines, oxaliplatin and 
irinotecan. The exposure to all there drugs during the 
course of  patients illness correlates strongly with median 
OS of  the patients with mCRC. Sequential use of  these 
drugs can sometimes be justified in order to reduce toxic 
effects and eventual exposure to all of  these drugs. The 
major caveats however to this approach include: not 
exploiting the synergistic potential of  the drugs, lack of  
intrinsic anti-tumour activity of  oxaliplatin as monother-
apy and tendency of  some patients to deteriorate prior 
to receiving all of  these drugs.
In patients where downsizing the tumour to optimise 
the chances of  surgery is an option, one of  the aims of  
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conversion chemotherapy should be to achieve the high-
est possible ORR. The association of  better ORR with 
improved resection rates has been previously demon-
strated[16]. It is also been reported that 12%-33% of  the 
patients who were treated with doublet chemotherapy 
regimen and had initially un-resectable CLM were able 
to achieve significant response so that they could un-
dergo surgery[13,58-60]. In addition, epidermal growth fac-
tor receptor (EGFR) targeted therapy along with two-
drug regimen resulted in one of  the highest ORR for 
CLM in patients with no mutations in Kirsten sarcoma 
virus (K-RAS) genes[32]. Also, CAPOX along with vascu-
lar endothelial growth factor (VEGF) targeted therapy 
with bevacizumab has been shown to result in similar 
ORR for CLM[61]. Both aforementioned studies demon-
strated similar R0/R1 liver resection rates after conver-
sion chemotherapy. Ye et al[62] performed one of  the first 
randomised studies of  chemotherapy with or without 
cetuximab in patients with unresectable CLM. This study 
did confirm the general belief  that chemotherapy plus 
cetuximab led to significantly higher ORR, liver resec-
tion rate, PFS and OS. The study therefore provided 
considerable weight to support the use of  chemotherapy 
plus cetuximab as a standard treatment option in the 
K-RAS wild type (WT) disease. Nevertheless, as the pri-
mary endpoint of  this study was the conversion rate to 
liver resection, the number of  patients included was rela-
tively small. The survival outcomes were only secondary 
endpoints and this could not be deemed to be definitive 
that chemotherapy plus cetuximab would improve OS, 
especially given the short follow up in this study. There-
fore there remains a need for a phase Ⅲ study to address 
this question. One of  the major strengths of  this study 
however, was the multi-disciplinary approach in the 
management of  patients with CLM. The authors chose 
the criteria of  unresectability which would be in line with 
modern international practice and given that this study 
was conducted in a single institution, it was likely that 
the decision-making process of  resectability was uniform 
and consistent both among patients as well as over time. 
It was however unclear both from the paper and the 
protocol of  the study as to what pre-treatment evalua-
tions were undertaken. United Kingdom-based phase Ⅲ 
study which randomised patients with KRAS WT CLM 
between surgery and surgery with chemotherapy along 
with cetuximab failed to show any survival advantage 
in favour of  cetuximab plus chemotherapy arm[63]. Al-
though the final results of  this study are still awaited, the 
proposed reasons for failure include heterogeneity of  
selected patient population (patients could represent ei-
ther resectable or un-resectable CLM with no restriction 
to number of  liver lesions) and use of  capecitabine and 
oxaliplatin in number of  patients in the study, which may 
not have synergised well with cetuximab, as previously 
demonstrated in the COIN study[64].
In recent times, the triplet FOLFOXIRI was inves-
tigated as first-line treatment in un-selected patients 
with mCRC and showed higher ORR (66% vs 41%, P = 
0.0002), and better secondary metastasectomy rate (15% 
vs 6%, P = 0.003) when compared to FOLFIRI[65]. PFS 
(9.8 mo vs 6.9 mo) and OS (22.6 mo vs 16.7 mo) were 
also both significantly better and in favour of  FOLFIX-
IRI. This trial however reported benefits in mCRC with 
all comers (with extra-hepatic disease) and thus the re-
sults couldn’t be interpreted in patients with CLM alone. 
Recently data from a phase Ⅱ study reported 5-year sur-
vival of  42% in patients who were converted by FOLF-
OXIRI to undergo liver resection[66]. In another phase Ⅱ 
study, the addition of  bevacizumab to FOLFOXIRI[67] 
resulted in ORR of  80% and R0 resection rate of  40% 
in patients with CLM. The ORR to FOLFOXIRI plus 
bevacizumab did not appear to be influenced by K-RAS 
or B-RAF mutational status of  the tumour. More recent-
ly, a randomised phase Ⅲ study showed a significant im-
provement of  PFS in patients receiving FOLFOXIRI + 
bevacizumab compared to those who received FOLFIRI 
+ bevacizumab[68]. Likewise, the addition of  another 
EGFR targeting drug, panitumumab to FOLFOXIRI 
resulted in ORR of  89%, with 43% patients undergo-
ing secondary for metastatic disease and R0 resection 
in 35% of  the patients with K-RAS WT patients was 
achieved in this single-arm phase Ⅱ study[69]. All these 
studies strengthen the need for conducting a randomised 
phase Ⅲ trial evaluating the role of  triplet chemotherapy 
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Figure 2  Computed tomography images. A: Computed tomography (CT) scan of a patient showing extensive liver metastatic disease prior to systemic therapy; B: 
CT scan after 4 cycles of neo-adjuvant chemotherapy demonstrating excellent partial response to the treatment along with intra-tumoural calcification; C: CT scan fol-
lowing left hepatectomy.
A B C
with targeted therapies in order to have more robust data 
to support the initial clinical findings.
With the current evidence, we support the view of  
using doublet chemotherapy with bevacizumab or cetux-
imab in K-RAS WT patients and that of  using doublet 
chemotherapy with bevacizumab in K-RAS mutant 
patients; however, where possible, triplet chemotherapy 
along with targeted agents should be considered.
Challenges associated with neo-adjuvant chemother-
apy for CLM: Although neo-adjuvant chemotherapy 
has the potential to convert initially un-resectable disease 
into resectable one for some patients, the frequency with 
which this happens is still relatively low. There are some 
important considerations in adapting this approach 
which are summarised below: (1) one of  the common 
concerns about the neo-adjuvant chemotherapy in 
initially resectable disease is the associated risk of  pro-
gression of  the disease due to delay in surgery. In the 
EORTC 40983 study, 7% of  the patients experienced 
progressive disease during the time of  pre-operative 
chemotherapy leading to un-resectability; half  of  them 
however had new lesions[56]. Some old reports indicate 
poor prognosis in such patients partly attributable to the 
inability to offer these patients surgical resection[70]; this 
concept has however been challenged in recent times 
with others suggesting that the progression of  disease 
rather reflects upon the aggressive disease biology and 
may in fact prevent unnecessary surgical morbidity or 
indeed mortality[14,71,72]; (2) with the recent advance-
ments in cytotoxic and targeted therapy regimens, and 
aggressive management of  CRC, radiological CR to the 
treatment can be observed in a proportion of  patients. 
This could lead to disappearance of  initially observed 
liver metastases and can pose a potential challenge for 
physicians to form an appropriate treatment strategy. 
Many published series have reported the increasing inci-
dence and management of  disappearing liver metastases 
(DLM) with variety of  chemotherapy regimens with out 
without hepatic arterial infusion (HIA)[73-81]. The rate of  
DLM has varied from 6.5% to 36%, partly due to the 
fact that CR is largely dependent on the quality of  pre-
operative imaging. It is important to recognise that CR 
on imaging doesn’t always mean complete pathological 
response. The true CR in the context of  CLM could be 
best defined as either complete pathological response 
or no recurrence of  the CLM, if  let in situ[82]. The rate 
of  reported pathological response in the CLM setting is 
largely variable, ranging from 9% to 58%[73,76,77,81,83]. This 
could be attributed to several heterogeneous factors in-
cluding the use of  HIA, number and size of  metastatic 
sites, disease biology, pre-operative imaging techniques 
and the number of  cycles and duration of  neo-adjuvant 
chemotherapy. When CLM are left in situ, after achieving 
CR on imaging, the recurrence rates have varied from 
38% to 74%[74,76]; however, this had no major impact on 
the OS of  the patients when the CLM were left in situ as 
the patients were offered re-resection or other localised 
treatments like RFA at the time of  recurrence[79]. The 
above discussion on DLM highlights the importance 
of  baseline and pre-operative imaging and the fact that 
there are currently no standard guidelines to manage 
DLM. All the imaging modalities including DW-MRI 
scan and PET scan should be utilised in order to be 
certain about the nature of  response to neo-adjuvant 
therapy; in the event of  definite CR, we adopt “watch 
and wait” policy in our institute with frequent clinical, 
and imaging monitoring of  these patients on 3-monthly 
basis during the first three years followed by 6-monthly 
imaging by CT scan for another two years. We suggest 
that for patients where DLM are left in situ, there should 
be a low threshold for repeating the imaging on any rise 
of  tumour markers or in the event of  clinical symptoms; 
(3) there are growing numbers of  reports suggesting 
liver toxicity as results of  neo-adjuvant chemotherapy. 
Whilst, oxaliplatin-based backbone is associated with 
risk of  increased vascular lesions, irinotecan-based 
combinations can cause steatohepatitis[84,85]. In addition 
chemotherapy carries risk of  systemic toxicities includ-
ing post-operative bleeding, neutropenia and associated 
infections, pot-operative complications and poorer func-
tional reserve in the presence of  vascular lesions. It is 
however re-assuring that the impact of  these complica-
tions on surgical mortality is insignificant; however, the 
impact on co-morbidities remains controversial in view 
of  conflicting evidence from different reports[85,86]. In 
addition, bevacizumab which is commonly used along 
with chemotherapy back-bone can theoretically increase 
the risk of  thrombo-embolic events including stroke 
and arterial thromboembolism, bowel perforation and 
wound healing. Nevertheless, our own experience and 
those of  others using chemotherapy in conjunction with 
bevacizumab is satisfactory and doesn’t seem to influ-
ence the liver regeneration after surgery[61,87]. Further-
more, some retrospective data suggests that addition of  
bevacizumab to oxaliplatin-based regimen may actually 
reduce the risk of  oxaliplatin induced liver toxicity[88-90]; 
and (4) we therefore suggest that all the patients should 
be individually assessed for the risk of  potential compli-
cations with neo-adjuvant therapy; however, this on its 
own shouldn’t deter the physicians from adopting the 
approach of  upfront systemic treatment. Because of  the 
half-life is bevacizumab (20 d), at least 3-wk interval be-
tween the last dose of  chemotherapy and surgery should 
be considered; thus the last treatment may be offered 
without bevacizumab. The choice of  chemotherapy 
regimen in relation to toxicities remains controversial 
and may depend on the local guidelines and physicians 
discretion.
Post-operative chemotherapy: Post-operative adjuvant 
chemotherapy has well-defined role in high-risk patients 
with CRC; however the data for adjuvant therapy in 
stage Ⅳ disease is still limited. Two randomised phase Ⅲ 
studies evaluated the role of  adjuvant treatment in this 
setting and their pooled analysis[91] the French FFCD 
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9002[92] and EORTC trials (n = 278 patients) showed 
median disease free survival (DFS) of  28 mo vs 19 mo 
(P = 0.058) and OS of  62 mo vs 47 mo in favour of  
chemotherapy (P = 0.095). Both trials used the same 
chemotherapy regimen of  5-FU and leucovorin, admin-
istered for five days consecutively in a 4-wk cycle for 
6 mo; however, both closed pre-maturely due to poor 
accrual. The improvement in DFS and OS was deemed 
statistically insignificant but could represent clinically 
meaningful advantage.
The major criticism on these trials was the choice of  
contemporary regimen which can be more toxic and pos-
sibly not active enough to reflect any significant advan-
tage. Post-operative treatment with irinotecan in addition 
to 5-FU in a multicenter phase Ⅲ trial showed no ad-
ditional benefit compared to 5-FU alone. Although there 
was a non-significant 3-mo increase in DFS (24.7 mo vs 
21.6 mo), the 3-year survival rates with combination were 
strikingly similar (73% vs 72%) to single agent therapy[93]. 
These results however need to be interpreted with caution 
as at least three previous adjuvant trials utilising FOLFIRI 
in stage Ⅱ/Ⅲ disease have failed to demonstrate any DFS 
benefit[94-96].
The role of  adjuvant chemotherapy in this setting 
remains controversial partly due to the poor accrual and 
pre-mature closure of  clinical trials designed to address 
this question; however, based on the benefit demon-
strated in several clinical trials in high-risk CRC patients, 
consideration should be given to adjuvant therapy par-
ticularly if  the patient gained benefit from neo-adjuvant 
therapy.
LOCALISED TREATMENT OPTIONS
RFA
RFA is a local ablative method which can be carried out 
using an open, laparoscopic or percutaneous technique; 
the choice of  procedure is often operator choice as there 
is not any current evidence to support a superior ap-
proach. Lesions along the inferior edge of  the liver and 
multiple lesions are difficult to treat with RFA. Lesions 
located close to large vessels (> 1 cm) may be incom-
pletely treated as the proximity of  a large vessel means 
optimal tissue heating cannot be achieved, so called 
the “heat sink effect”[97]. In these cases other treatment 
methods may be more appropriate.
RFA is performed under local or general anaesthesia; 
a high frequency alternating current is applied through 
needle electrodes which are placed under imaging guid-
ance, either with CT or ultrasound. Heat is generated 
which results in localised coagulative necrosis and causes 
destruction of  the tumour [National Institute of  Clini-
cal Excellence (NICE), radiofrequency ablation for 
colorectal liver metastases 2009]. RFA is a relatively well-
tolerated procedure; however the reported complications 
range from 6%-9% with mortality of  0%-2%[98]. These 
include liver abscess, pleural effusions, pneumothorax, 
acute renal insufficiency and hypoxemia.
The NICE guidelines recommend that RFA is used 
to treat CLM in patients who are unfit or unsuitable for 
surgery, for those with recurrent disease or increasingly 
as an adjunct to hepatic resection as a curative treatment 
option (NICE, radiofrequency ablation for colorectal 
liver metastases 2009). In addition RFA may be used re-
peatedly to achieve local tumour control.
The CLOCC study was a prospective trial which 
examined the use of  RFA in patients with CLM. This 
randomised phase Ⅱ study aimed to establish the added 
benefits of  using RFA in addition to chemotherapy in 
patients with unresectable liver metastases but no extra-
hepatic disease[99]. One hundred and nineteen patients 
were recruited in the study; of  those 59 patients had 
chemotherapy alone, 60 had chemotherapy and RFA. 
Median PFS was 16.8 mo in the RFA + chemotherapy 
group, compared to 9.9 mo in the chemotherapy alone 
group (P = 0.025). Thirty-month OS was 61.7% in 
the RFA + chemotherapy arm, and 57.6% in the che-
motherapy alone arm. The authors concluded that the 
benefit of  RFA in the treatment of  liver metastases was 
uncertain and further work was required. Otherwise, 
the published data on efficacy of  RFA in CRC mostly 
comprises of  retrospective series and requires cautious 
interpretation. Minami et al[100] performed a review of  
local tumour progression and OS after RFA and found 
variable local recurrence rates after RFA (ranging from 
8.8% to 40%) and described that 5-year OS ranged from 
20% to 48.5%. The authors also reviewed the survival 
rates after RFA in comparison to survival after hepatic 
resection. For the majority of  published papers OS after 
RFA was significantly less than survival after hepatic re-
section[25,101,102]. The authors summarised that this differ-
ence may be due to the selection bias as RFA was mostly 
used in patients who are unsuitable for hepatic resection 
and thus may represent aggressive disease biology.
The variable and high local tumour progression rates 
may limit the use of  RFA. Some authors have therefore 
tried to identify factors which affect tumour progression; 
to date blood vessel proximity, the size of  the metastasis 
and the size of  the radiofrequency ablation margin have 
been shown to affect local recurrence rates in small se-
ries[24,103,104]. Although further work is required to validate 
these findings, we suggest that these factors should be 
carefully considered when offering RFA to the patients 
with CLM.
SIRT: SIRT with or without chemotherapy can be used 
to treat patients with CLM alone, or patients with lim-
ited extrahepatic disease. Localised high dose radiation 
is applied to the metastases by the embolisation of  small 
vessels around the metastases. It is indicated for patients 
who are unsuitable for treatment with surgery or abla-
tion. As with local ablation the treatment can be repeated 
(NICE IPG401 selective internal radiation therapy for 
non-resectable colorectal metastases in the liver 2011).
To date only small randomised controlled trials 
have been performed but some have been able to show 
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improved median survival when SIRT was used with 
systemic chemotherapy compared to systemic chemo-
therapy alone[105] and improved tumour response when 
SIRT was used with hepatic artery chemotherapy (HAC) 
compared to HAC alone[106].
SIRT may be potentially beneficial for the treatment 
of  unresectable CLM but more research is required to 
demonstrate its efficacy and to establish the potential 
use of  SIRT in treatment naive liver metastases (NICE, 
2011).
HIA CT: HIA chemotherapy with or without systemic 
therapy can be used to downstage the tumour size or 
following metastasectomy; based on the biological ra-
tionale that liver metastases primarily derive their blood 
supply from the hepatic artery. Some studies have shown 
encouraging results with HIA following metastasectomy; 
however, sample sizes have often been small[107,108]. A 
large randomised trial aiming to address the question of  
post-operative HIA was closed pre-maturely due to poor 
accrual[109], while another study was closed prematurely 
on grounds of  worst outcome[110]. The combination of  
systemic chemotherapy with HIA has been evaluated 
in a phase Ⅰ study[111]. This study recruited 49 patients. 
Patients were treated with HIA plus systemic oxaliplatin 
and irinotecan. ORR was 92% with 8% CR and 84% PR. 
43% of  the patients were able to undergo resection of  
the tumour, with free margins in 19. Median OS for the 
entire cohort was 40 mo.
Although these results were promising, and also some 
other studies utilising this approach with various chemo-
therapy regimens showed improvement in the rate of  
hepatic recurrence and recurrence-free survival[112]; OS 
benefit was not gained with this approach[112,113]. HIA has 
not so far been evaluated in large randomised clinical tri-
als and is not routinely used in many parts of  the world 
in management of  CLM.
Other local ablative methods: Microwave ablation and 
cryotherapy are other ablative techniques which are used 
to treat CLM. These also suffer from problems of  high 
local progression rates and the lack of  prospective data. 
Pathak et al[114] performed a systematic review of  the use 
of  ablative methods for CLM. They found variable lo-
cal progression rates and OS for RFA as Minami et al[100]. 
Twenty six cryotherapy studies were included showing, 
local progression rates of  12%-39% and mean 5-year 
overall survival of  17%. Thirteen microwave studies, 
also showed variable local progression rates (5%-13%) 
and mean 5- year OS of  16%.
Local ablative techniques are increasingly used for 
patients with CLM, in both a curative and palliative set-
ting. RFA, cryotherapy and microwave ablation have the 
potential to improve survival for patients with CLM; 
however these techniques are hampered by variable local 
progression rates and survival rates are lower than those 
for curative resection. Evaluation in large randomised 
trials is required to further clarify the emerging role of  
local ablation.
OTHER IMPORTANT CONSIDERATIONS 
IN MANAGEMENT OF CLM
CLM with limited extra-hepatic disease
The presence of  both synchronous liver and lung me-
tastases doesn’t necessarily represent an absolute contra-
indication to surgery, as long as complete resection of  
all metastatic sites is possible. One of  the earlier studies 
reported on the outcome of  a series of  165 patients with 
mCRC with 5 and 10 year survival rates of  39.6% and 
37.2% respectively in un-selected population. Those pa-
tients who underwent hepatic metastasectomy (n = 26) 
had 10 year survival of  34.1%; 21 patients had two or 
three thoracotomies for recurrent CRC and for those the 
reported 5 year survival was 52.1 mo from the time of  
second thoracotomy. Patients with hilar or mediastinal 
lymph nodes had the worst outcome with 5-year survival 
of  6.2%[115]. Another study including 63 patients with 
either lung only metastases (group 1, n = 45) or synchro-
nous lung and liver metastases (group 2, n = 18), treated 
aggressively with surgery showed no significant differ-
ence in survival at median follow-up of  24 and 27 mo 
respectively in the two groups[45]. More recently, Gonzalez 
et al[116] conducted retrospective analysis of  27 consecu-
tive patients who underwent lung resection after previ-
ous hepatic metastasectomy for CRC. They reported 3 
and 5-year survivals of  56% and 39% respectively with a 
median survival of  46 mo. Likewise, another recent study 
reported on the outcome of  sixty-five patients who un-
derwent surgery for liver and lung metastases from CRC. 
In 33 cases, the first distant metastasis was diagnosed 
synchronously with the primary tumour; for the remain-
ing, median time interval between primary tumour and 
first distant metastasis was 18 mo (5-69 mo). Five- and 
10-year survival rates for all patients were 57% and 15% 
from diagnosis of  the primary tumour, 37% and 14% 
from resection of  the first metastasis and 20% and 15% 
from resection of  the second metastasis. After complete 
resection, 5- and 10-year survival rates improved to 61% 
and 18%, 43% and 17%, and 25% and 19%, in the three 
scenarios respectively. Negative margins (P = 0.002), the 
absence of  pulmonary involvement in synchronous me-
tastases (P = 0.0003) and single metastases in both organs 
(P = 0.036) were associated with a better prognosis[117]. 
Some other studies also illustrated the importance of  of-
fering surgical resection in this context, where possible[118].
Although these data are largely based on retrospective 
experience of  various institutes, considering the difficulty 
in designing prospective studies to evaluate outcome of  
patients with limited extra-hepatic disease in the presence 
of  CLM, and based on our own experience[119,120], we feel 
that aggressive surgical management of  CLM patients 
should still be considered where synchronous or meta-
chronous limited extra-hepatic disease can be potentially 
resected.
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Re-resection of CLM or oligo-metastatic disease
Up to 70% of  the patients, who had hepatic resection 
for CLM, could present with recurrent disease and the 
most frequent site of  recurrence is liver[19,121,122]. In the 
presence of  controlled primary disease, recurrent he-
patic metastases could be a result of  the development of  
occult tumours not detected at the time of  initial resec-
tion or with more recent evidence, could represent me-
tastases from the previous hepatic secondary[123,124]. Lung 
is the second most common site of  metastatic disease 
from CRC; however, the frequency of  isolated lung me-
tastases with CRC is 1%-5%. Lung metastases tend to be 
more commonly associated with rectal rather than colon 
primary[125]. This perhaps suggests that majority of  pul-
monary metastatic disease grows from the CLM[126,127].
Regardless of  the pathophysiology, re-resection of  
oligo-metastatic disease, where possible has been the only 
treatment modality that has shown improvement in long-
term survival[46,128-130]; in the absence of  randomised con-
trolled trials, these data are valuable and demonstrate the 
safety of  the aggressive surgical approach[131-136]. There is 
however some conflicting evidence questioning the ef-
ficacy of  re-resection[137]; nevertheless, most reported se-
ries show promise with achievement of  better long-term 
survival[138,139].
 We suggest offering surgical resection in the event 
of  recurrence; however, careful consideration should be 
given to the disease biology, relapse-free interval from 
the last resection, extent of  metastatic disease and co-
morbidity status of  the patients.
CHALLENGES AND FUTURE DIRECTIONS
Molecular complexity in CRC
The complex stepwise process of  CRC tumorigenesis 
was first proposed by Vogelstein two decades ago[140]. 
Over the years, our understanding about the heterogene-
ity in CRC tumorigenesis has improved exponentially. 
Traditionally, CRC is biologically divided into those with 
microsatellite instability (MSI) which is frequently associ-
ated with CpG island methylator phenotype and hyper-
mutation and those with microsatellite stable but chro-
mosomally unstable disease[141]. Other investigators[142,143] 
unfolded the critically important genes and pathways 
important to CRC tumorigenesis; those included WNT, 
RAS-RAF-MAP, P53 and DNA mismatch-repair path-
ways[144]. In 2012, the cancer genome atlas network pub-
lished results of  molecular characterization performed 
in CRC[145]. Genome-scale analysis comprising of  whole 
exome sequencing, DNA copy number, promoter meth-
ylation, messenger RNA and microRNA expression were 
performed on 276 samples with CRC. This consortium 
highlighted the complex molecular biology of  CRC; 16% 
of  CRC were found to have hypermutation (75% with 
expected high MSI and 25% with somatic mis-match re-
pair gene). Excluding the hypermutated patients, 24 genes 
were mutated in other patients; of  those APC, TP53, 
SMAD4, PIK3CA were previously established relevant 
mutations in the context of  CRC. Additionally, ARID1A, 
SOX9 and FAM123B were also found to be frequent mu-
tations, which were not previously defined as common 
mutations in CRC. WNT signalling pathway was found to 
be altered in 93% of  all tumours[145]. All these data high-
light the genetic complexity of  CRC and associated sig-
nificant challenges in management of  this disease. At the 
same time, this however, allows a wide window of  op-
portunity for further research in order to form effective 
and more robust strategies in targeting these pathways.
Heterogeneity between the primary and secondary CRC
Intra-tumour heterogeneity is a well-established phe-
nomenon which can contribute to treatment failures and 
drug resistance in various malignancies[123,146-151]. Other 
important consideration is the heterogeneity of  muta-
tions between the primary and the secondary tumours. 
This is particularly important in the context of  CRC, as 
treatment plan could vary significantly based on the RAS 
status of  the tumour. Several studies have examined the 
heterogeneity of  CRC and any existence of  discordance 
in the mutations between primary and secondary tumour 
with variable results. Baldus et al[152] found that heteroge-
neity between primary and secondary tumours in CRC 
samples was present in 10% for KRAS and 5% with 
PIK3CA mutations. A large systemic review included 21 
studies, examining the concordance of  KRAS between 
the primary CRC and metastases. This study found an 
overall concordance rate of  93% (range 76%-100%), 
98% and 68% in KRAS, BRAF and PTEN loss respec-
tively[153]. It is however noteworthy that KRAS mutation 
has always been considered as one of  the early events in 
CRC tumorigenesis[140,154]; nevertheless, the small rates of  
discordance may have an impact on the choice of  treat-
ment as KRAS/RAS is currently the only validated bio-
marker in management of  CRC. The molecular profiling 
of  primary and metastatic disease in modern era will 
perhaps further unfold the late events causing heteroge-
neity of  the primary tumour followed by progression of  
one clone, resulting in metastases[142]. Given that CLM 
patients can potentially live longer than they used to live 
a decade ago, the development of  late mutations leading 
to drug resistance will become more relevant in the con-
text of  systemic management of  CLM.
Emerging therapies
A variety of  drugs are under evaluation in management 
of  CRC. They can be broadly divided into growth factor 
receptor inhibitors targeting EGFR and VEGF path-
ways, RAS pathway inhibitors and PI3K-AKT-mTOR 
pathway inhibitors. There is also growing interest in 
targeting WNT pathway due to the frequent aberration 
of  this pathway in CRC. At the same time, there remain 
challenges in aberrant compensatory pathways, which 
could lead to resistance to these targeted therapies. Ad-
ditionally, the druggability of  these targets is yet under 
evaluation. The two new agents approved by United 
States Food and Drug Administration are regorafenib 
12399 September 21, 2014|Volume 20|Issue 35|WJG|www.wjgnet.com
Khan K et al . Colorectal cancer with liver metastases
and aflibercept[155-158]. These new drugs are likely to be 
investigated in clinical trial setting in the management 
of  CLM, particularly in patients with disease, which 
is deemed borderline or un-resectable at the outset. 
There are several other new drugs under evaluation 
in phase Ⅰ setting as single agent and as combina-
tions[159-161]; these may become part of  armoury of  CRC 
management in future.
CONCLUSION
CRC is one of  the commonest cancers with high inci-
dence and mortality associated with metastatic disease. 
Vast majority of  patients with metastatic disease may pres-
ent with CLM; of  those some have CLM alone or in the 
presence of  limited extra-hepatic disease. Surgical resec-
tion of  CLM, where possible remains the most effective 
treatment to achieve long-term cure; however, optimal 
patient selection with utility of  available imaging tech-
niques and comprehensive multi-disciplinary involvement 
is paramount to avoiding un-necessary surgical complica-
tions and achieving long-term cure.
Where R0 resection is possible, perioperative chemo-
therapy should be considered for three months preop-
erativey followed by another three months of  postopera-
tive chemotherapy.
For patients where R0 resection is not possible, ag-
gressive preoperative chemotherapy approach with EGFR 
or VEGFR targeted therapy along with chemotherapy 
backbone of  FOLFOX or FOLFIRI should be consid-
ered. Where possible, either in the context of  clinical 
trials or local availability of  drugs, triplet chemotherapy 
should be encouraged as this can potentially increase the 
chances of  resectability by optimising the response to the 
treatment. For patients who present with synchronous 
CLM, the optimal timing for resection of  primary and 
the metastatic disease is uncertain. One-stage surgery 
with resection of  both primary and the secondary can be 
considered, where surgical expertise allow that; otherwise 
resection of  CLM could be performed 6-8 wk after re-
section of  the primary or vice versa. The role of  localised 
treatments as an adjunct to systemic therapy and surgery 
is rather uncertain but these approaches can be consid-
ered on case-to-case basis.
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